The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
ASH 2018 | Phase I study of HCG/EGF adjunct therapy in high-risk and steroid refractory acute graft-versus-host disease
On Saturday 1 December 2018, an oral abstract session took place at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. During Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: GVHD Grading and Outcomes and Management, Abstract #71 was presented by Shernan G. Holtan, University of Minnesota, Minneapolis, MN, USA, entitled: Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin (hCG) and Epidermal Growth Factor (EGF) (Pregnyl): A Phase I Study.
This phase I study was conducted to evaluate hCG/EGF in patients with Minnesota High Risk and steroid dependent or refractory acute graft-versus-host disease (aGvHD) to improve both hCG-mediated immunologic tolerance and tissue repair via supplemental EGF. Urinary-derived hCG (Pregnyl®) was given to patients with aGvHD in addition to standard of care.
Patients and methods
N = 26 patients
- Arm 1: N = 13 patients (median age = 65 years) were high-risk and received first line Pregnyl® SQ QOD for 7 days
- Arm 2: N = 13 patients (median age = 65 years) were steroid refractory and received Pregnyl® as second line treatment SQ QOD for 14 days
Key findings
- hCG/EGF was well tolerated, with no dose-limiting toxicities
- Median EGF dose: 50,833 pg/ml
- Most common treatment emergent adverse event was edema in 16 patients (62%)
- Proportion of day-28 response
- Arm 1:
- CR: 62%
- PR: 0
- NR: 38%
- Arm 2:
- CR: 54%
- PR: 8%
- NR: 38%
- Pregnyl® does not worsen cytopenias
- Pregnyl® increases serum hCG, estradiol, and testosterone; all returned to baseline by day 56
- Pregnyl® may support Treg/Tcon ratio
- AREG significantly decreases over time in patients with day-28 CR/PR
- Arm 1:
In conclusion, Pregnyl® appears “safe and feasible supportive care in first and second line severe aGvHD.” Pregnyl® may facilitate tolerance and tissue repair, without adding to side-effects of GvHD treatment. Doctor Holtan added that “the optimal dose and duration of hCG/EGF are under investigation, with ongoing dose escalation in patients with steroid-refractory aGvHD based upon these initial results.”
References